As of September 30, 2024, the company had cash, cash equivalents and marketable securities of $202.8 million, which is expected to fund our operating expenses and capital expenditure requirements into the second half of 2026.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics to presents data on deployment of AP3 platform
- Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline
- Acrivon announces initial patient dosing in Phase 1 trial of ACR-2316
- Acrivon Therapeutics price target raised to $28 from $25 at BMO Capital
- Acrivon Therapeutics: Promising Trial Results and FDA Clearance